自身免疫新玩家:Prolium携康诺亚/诺诚健华的TCE登场,获得5000万美元A轮融资

Minhua笔记
Mar 04

一家全新的生物技术公司 Prolium Bioscience 正式亮相,并一出手就拿下 5,000 万美元 A 轮融资。该公司的唯一资产 PR‑203,来自康诺亚和诺诚健华的授权。RTW 领投 5,000 万美元,只押一个资产Prolium 于3月3日宣布完成 5,000 万美元 A 轮融资,由知名生命科学投资机构 RTW Investments 独家支持。公司成立伊始的目标非常明确:推进一款 T...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10